Brief: Green Cross Corp Receives Market Approval For ‘Alyglo,’ Used For Treating Primary Humoral Immunodeficiency, From The U.S. Food And Drug Administration
18/12/2023 01:44
GC Biopharma Corp 006280.KS :
* GREEN CROSS CORP: RECEIVES MARKET APPROVAL FOR ‘ALYGLO,’
USED
FOR TREATING PRIMARY HUMORAL IMMUNODEFICIENCY, FROM THE U.S.
FOOD AND DRUG ADMINISTRATION
Source text for Eikon: ID:
Further company coverage: 006280.KS
Recent news on GC Biopharma
See all newsBrief: Gc Biopharma Q2 Operating. Profit 1.7 Billion Won, Down 93.8% Y/Y
Brief: Gc Biopharma Corp 006280.Ks - Q1 Operating. Profit 11.7 Billion Won, Up 46% Y/Y
Brief: Green Cross Corp Q3 Operating Profit 29.2 Billion Won, Down 26.3% From Year Earlier
Brief: GC Biopharma gets CMO rights for shingles vaccine from Curevo Vaccine
Brief: Gc Biopharma Receives Marketing Authorization For Barycela In Vietnam